Defence Therapeutics
Corporate brand
UnclaimedDefence Therapeutics is a publicly traded precision intracellular drug-delivery company unlocking the full potential of cancer biologics.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Defence Therapeutics is a publicly traded Canadian biotechnology company focused on precision intracellular drug delivery. Its proprietary Accum® platform enhances intracellular delivery, increasing potency while reducing toxicity in ADCs, radiopharmaceuticals, and other advanced biologic therapies. The company aims to transform existing and next-generation biologics into safer, more effective first-line treatments.
History
Defence Therapeutics is a publicly traded precision intracellular drug-delivery company. It is a Canadian biotechnology company using its Accum® platform to enhance the potency of ADCs and other complex biologics at lower doses.
Recent events
Reported
Defence Therapeutics appoints Riam Shammaa to its board[3]
Defence Therapeutics announced the appointment of Dr. Riam Shammaa to its board of directors, effective immediately.
Reported
Defence Therapeutics and Curie Institute establish collaboration[4]
Defence Therapeutics announced a collaboration with the Curie Institute to evaluate Accum-T-DM1 ADC's therapeutic efficacy in patient-derived xenograft models of breast cancer.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/defence-therapeutics · Editorial policy · How profiles are compiled